395 articles with Medivir AB
Medivir AB announces that the company will present at the virtual meeting Redeye Growth Day on June 2, 2021.
Medivir AB announced the details of its upcoming phase 1/2a combination study with the company's leading candidate drug, MIV-818, against liver cancer.
Medivir AB announces that the company will present at the virtual meeting ABGSC Life Science Summit, , May 25.
Positive results from investigator-initiated phase II clinical study of remetinostat in patients with squamous cell carcinoma published
Medivir AB announces that results from the investigator-initiated phase II clinical study in patients with squamous cell carcinoma.
In January the company signed an exclusive license agreement with IGM Biosciences, Inc. for birinapant. Medivir received a payment of USD 1 million after signing, which is to be followed by an additional USD 1.5 million when IGM includes birinapant in phase I clinical trials.
Medivir AB announces that the company will participate at the virtual meeting Kempen Life Sciences Conference - 2021 Thematic Virtual Series, on April 21.
Medivir AB (Nasdaq Stockholm: MVIR) today announced that the last patient has undergone the safety follow-up to identify potentially dose-limiting toxicity from the first part of the phase Ib study with the company's leading candidate drug, MIV-818, against liver cancer.
Medivir AB announced that its Board of Directors appoints Magnus Christensen, the company's CFO, as interim CEO of Medivir.
Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2020 now is available at the company's website: www.medivir.com . In the spring of 2020,
Medivir AB announces that the number of shares and votes in Medivir has changed during March 2021 as a result of the previously announced directed issue to Linc AB which in total resulted in an increase of 3,600,000 class B shares.
The shareholders of Medivir AB, reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to the annual general meeting on Wednesday 5 May 2021.
Last patient with liver cancer included in the monotherapy part of Medivir's phase Ib study with MIV-818
Medivir AB announced that the last patient with advanced liver cancer has been included in the first part of the phase Ib study with MIV-818.
The extraordinary general meeting in Medivir Aktiebolag on 11 March 2021 resolved, in accordance with the board of directors' proposal, to raise approximately SEK 27,828,000 by a directed issue of not more than 3,600,000 new class B shares.
Medivir AB announces that the company will present at the virtual meeting H.C. Wainwright Global Life Sciences Conference, March 9-10.
In October Dr. Tom Morris was appointed interim Chief Medical Officer. Dr. Morris is a member of Medivir's management team and reports to CEO Yilmaz Mahshid.
Medivir Proposes Directed Issue of Approximately SEK 28 Million to the Company's Existing Specialist Investor LINC
The Board of Directors in Medivir AB has decided to summon an extraordinary general meeting on 11 March 2021 to propose a directed issue to the Company's existing specialist investor LINC AB, controlled by the Company's board member Bengt Julander.
The extraordinary general meeting in Medivir Aktiebolag on 13 January 2021 resolved, in accordance with the board of directors' proposal, to decrease the company's share capital with SEK 20,908,234.356976 without cancellation of shares.
Medivir AB announces that a presentation entitled "Phase I study of the novel pro-drug MIV-818 in patients with hepatocellular carcinoma, intra-hepatic cholangiocarcinoma or liver metastases" will be given by Professor Jeff Evans, Director of Institute of Cancer Sciences at University of Glasgow, at the virtual ASCO Gastrointestinal Cancers Symposium.
IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant- IGM to Develop Birinapant in Combination with IGM-8444 for the Treatment of Solid Tumors -
IGM Biosciences, Inc. (Nasdaq: IGMS) today announced that it has entered into an exclusive license agreement with Medivir AB (Nasdaq Stockholm: MVIR), through which IGM will receive global, exclusive development and commercialization rights for birinapant, a clinical-stage SMAC mimetic that binds to and degrades Inhibitors of Apoptosis Proteins (IAPs), leading to cell death (apoptosis) in tumor cells. The combination of IGM-8444, an IgM
The shareholders of Medivir AB, reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to the extraordinary general meeting on Wednesday 13 January 2021.